"Lancet"[JOURNAL]

Chronic kidney disease affects 850 million people worldwide and places a disproportionate burden on low-income and middle-income countries where access to timely diagnosis, treatment, and life-sustaining kidney replaceme... Chronic kidney disease affects 850 million people worldwide and places a disproportionate burden on low-income and middle-income countries where access to timely diagnosis, treatment, and life-sustaining kidney replacement therapy (KRT) is restricted. In May, 2025, the 78th World Health Assembly adopted a resolution on kidney health that called on all member states to integrate kidney care into national strategies; enhance prevention, early detection, and timely management; strengthen primary care; expand access to KRT; and enhance capacity for measuring burden, progress, and return on investment. These ambitious commitments were followed by the Political Declaration of the UN High-Level Meeting on NCDs and Mental Health. Capitalising on the opportunities created by these two initiatives will depend on governance, political commitment, and accountability, along with technical tools, appropriate funding, and mechanisms to measure progress. This Health Policy offers a practical framework to help governments and partners operationalise the commitments from the resolution and political declaration, drawing on lessons from other non-communicable disease programmes and on countries' experiences with kidney health policy.

Get PDF PubMed ↗

Johns Hopkins Center for Humanitarian Health-Lancet Commission on health, conflict, and forced displacement: health in a world of crises and impunity.

Spiegel P, Martinez E, Abrahim O … +45 more , Undie CC, Altare C, Schmid B, Abbara A, Bahattab A, Bojorquez I, Cantor D, Jouhaud R, Alier KK, Maxwell D, Moya A, Ontas E, Rashid SF, Rao M, Slim H, Abdelhay A, Basaleem H, Bisimwa G, Fouad FM, Liu J, Meda N, Pantuliano S, Zaman M, Alkhalil M, Falb K, Holloway K, Jahan I, Kannan T, Lindsay H, Mwene-Batu P, Misha F, Bielska IA, Modi KEN, Muthuri S, Niaoné M, Bou-Orm IR, Rodriguez C, Sadaf A, Saadi A, Polinori C, Franck CP, Kampalath V, Polonsky J, Randriambelonoro MM, Blanchet K

Lancet · 2026 May · PMID 42155503 · Publisher ↗

For the French, Spanish and Arabic translations of the abstract see Supplementary Materials section. For the French, Spanish and Arabic translations of the abstract see Supplementary Materials section.

Get PDF PubMed ↗

A much-needed reboot for international solidarity.

Egeland J

Lancet · 2026 May · PMID 42155502 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Making mutual aid the architecture of humanitarian response.

Ahmed H

Lancet · 2026 May · PMID 42155501 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Meeting the 2024 UN General Assembly declaration targets on antimicrobial resistance.

Laxminarayan R, Limmathurotsakul D, de Abreu AL … +5 more , Alimi Y, Karkey A, Kanj SS, Mendelson M, Cars O

Lancet · 2026 May · PMID 42155500 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Department of Error.

Lancet · 2026 Jun · PMID 42155499 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials.

Papi A, Greening NJ, Bhatt SP … +26 more , Roche N, Celli B, Wedzicha JA, Agustí À, Tal-Singer R, Han MK, Janssens W, Hanania NA, Nair P, Bremner P, Porpodis K, Shibata Y, Korn S, Yang T, Gordon O, Saenz R, Ng J, Cheung DS, Devine J, Grimbaldeston MA, Zhang W, Yang X, Mohan D, Vogelmeier CF, Brightling CE, ALIENTO and ARNASA investigators

Lancet · 2026 May · PMID 42150581 · Publisher ↗

BACKGROUND: Interleukin-33 and its receptor, ST2, are implicated in neutrophilic and eosinophilic inflammation during chronic obstructive pulmonary disease (COPD) exacerbations. We aimed to assess the efficacy and safety... BACKGROUND: Interleukin-33 and its receptor, ST2, are implicated in neutrophilic and eosinophilic inflammation during chronic obstructive pulmonary disease (COPD) exacerbations. We aimed to assess the efficacy and safety of astegolimab, an anti-ST2 human IgG2 monoclonal antibody, which were evaluated in two COPD pivotal trials. METHODS: In two randomised, double-blind, placebo-controlled trials (phase 2b ALIENTO and phase 3 ARNASA), current or former smokers with COPD and a history of frequent exacerbations, irrespective of baseline blood eosinophils, were randomly assigned (1:1:1; stratification by smoking status and region) to receive subcutaneous astegolimab 476 mg every 2 weeks, every 4 weeks, or placebo, alongside optimised inhaled maintenance therapy over 52 weeks. The primary endpoint (analysed in participants receiving one or more doses) was annualised rate of moderate or severe exacerbations. Missing data were considered similar to data from other participants in the same treatment group with the same baseline characteristics. The trials were registered with ClinicalTrials.gov (NCT05037929 and NCT05595642). FINDINGS: In ALIENTO, 1301 participants (astegolimab every 2 weeks, n=433; astegolimab every 4 weeks, n=437; and placebo, n=431) initiated treatment between Oct 5, 2021, and Feb 19, 2024. In ARNASA, 1375 participants (astegolimab every 2 weeks, n=459; astegolimab every 4 weeks, n=459; and placebo, n=457) initiated treatment between Jan 9, 2023, and June 25, 2024. Adjusted rate ratios versus placebo for the primary endpoint were 0·85 (95% CI 0·72-1·00; p=0·049) for astegolimab every 2 weeks and 0·93 (0·79-1·10; p=0·38) for astegolimab every 4 weeks in ALIENTO, and 0·85 (0·72-1·01; p=0·068) for astegolimab every 2 weeks and 0·82 (0·70-0·98; p=0·024) for astegolimab every 4 weeks in ARNASA. Adverse events were balanced between treatments, with most participants experiencing one or more adverse events (1093 [84·0%] of 1301 participants in ALIENTO and 1176 [85·5%] of 1375 in ARNASA). The most common non-COPD adverse event was nasopharyngitis in ALIENTO and upper respiratory chest infection in ARNASA. Deaths occurred in 40 (3·1%) of 1301 participants in ALIENTO and in 44 (3·2%) of 1375 participants in ARNASA, and were balanced across treatment groups. Across both trials, a total of three deaths (0·1%) were considered to be related to treatment by investigators. INTERPRETATION: In ALIENTO, astegolimab every 2 weeks was associated with a lower annual rate of exacerbations versus placebo in patients with COPD and a history of frequent exacerbations. In ARNASA, these findings did not meet statistical significance. Together, these findings suggest a role for targeting the ST2/IL-33 pathway to reduce the frequency of COPD exacerbations in patients with limited treatment options. FUNDING: Genentech, a member of the Roche Group, and F Hoffmann-La Roche.

Get PDF PubMed ↗

"Lancet"[JOURNAL]

About